



Manufacturer's Information

Test No. 17-5803: DNA-Blood

Each sample pack consisted of two known bloodstains on FTA Micro cards (Items 1 & 2), and two questioned stains; one on clean, light purple material (Item 3) and one on clean, light blue material (Item 4). Participants were requested to analyze these items using their existing protocols.

SAMPLE PREPARATION: All stains were prepared from human whole blood which was either drawn into citric acid preservative blood bags or EDTA tubes. Items 1 (75 μ l) and 4 (50 μ l) were both created using blood collected from the same female donor. Items 2 (75 μ l) and 3 (50 μ l) were both created using blood collected from the same male donor. Stains from different sources were prepared at separate times and were packaged once they were thoroughly dried. Completed sample sets were stored at -20°C until shipment on April 17, 2017 following receipt of predistribution results.

SAMPLE SET ASSEMBLY: For each sample set, all four Items (1-4) were placed in a pre-labeled sample pack envelope. The sealed sample pack envelopes were then packaged in pre-labeled heat seal envelopes and sealed. This process was repeated until all of the sample sets were prepared.

VERIFICATION: Laboratories that conducted predistribution analysis of the samples reported consistent results and associations.

Manufacturer's Information, continued
Test No. 17-5803: DNA-Blood

Amelogenin and STR Results

Results compiled from predistribution laboratories and a consensus of at least 10 participants.

Item	D1S1656	D2S1338	D2S441	D3S1358	D4S2408	D5S818
	D6S1043	D7S820	D8S1179	D9S1122	D10S1248	D12S391
	D13S317	D16S539	D17S1301	D18S51	D19S433	D20S482
	D21S11	D22S1045	Amelogenin	CSF1PO	FGA	Penta D
	Penta E	SE33	TH01	TPOX	vWA	
1	14,16	23,24	10,11.3	16,18	*	11,13
	*	8,12	14,16	*	14,15	18,20
	9,11	11,13	*	12,14	14,15.2	*
	30,31.2	11,15	X,X	10,13	22,24	9,9
	7,10	16,23.2	7,9.3	10,12	15,17	
2	12,17	16,18	11,14	15,15	*	12,13
	*	10,10	14,15	*	13,17	16,19
	12,14	9,14	*	17,19	13,2,14	*
	29,31	17,17	X,Y	10,11	23,24	11,11
	5,5	19,29.2	7,7	8,11	17,17	
3	12,17	16,18	11,14	15,15	*	12,13
	*	10,10	14,15	*	13,17	16,19
	12,14	9,14	*	17,19	13,2,14	*
	29,31	17,17	X,Y	10,11	23,24	11,11
	5,5	19,29.2	7,7	8,11	17,17	
4	14,16	23,24	10,11.3	16,18	*	11,13
	*	8,12	14,16	*	14,15	18,20
	9,11	11,13	*	12,14	14,15.2	*
	30,31.2	11,15	X,X	10,13	22,24	9,9
	7,10	16,23.2	7,9.3	10,12	15,17	

YSTR Results

Results compiled from predistribution laboratories and a consensus of at least 10 participants.

Item	DYF387S1	DYS19	DYS385	DYS389-I	DYS389-II	DYS390	DYS391	DYS392	DYS393	DYS437	
	DYS438	DYS439	DYS448	DYS449	DYS456	DYS458	DYS460	DYS481	DYS505	DYS518	
	DYS522	DYS533	DYS549	DYS570	DYS576	DYS612	DYS627	DYS635	DYS643	YGATAH4	Y Indel
2	*	16	15,17	14	32	23	10	11	13	14	
	11	12	21	*	15	16	*	25	*	*	
	*	11	11	14	15	*	*	22	13	10	2
3	*	16	15,17	14	32	23	10	11	13	14	
	11	12	21	*	15	16	*	25	*	*	
	*	11	11	14	15	*	*	22	13	10	2

* Results were not received by a minimum of 10 participants for the STR or YSTR loci indicated.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.